| Literature DB >> 34236799 |
Valdano Manuel1,2, Leonardo A Miana1, Gustavo Pampolha Guerreiro1, Aida Turquetto1, Rômullo Medeiros Santos1, Natália Fernandes1, Davi Freitas Tenório1, Luiz Fernando Caneo1, Fabio B Jatene1, Marcelo Biscegli Jatene1.
Abstract
INTRODUCTION: Elevated neutrophil-lymphocyte ratio (NLR) has been associated with poorer outcomes in cyanotic patients undergoing single ventricle palliation. Little is known about this biomarker on patients with tetralogy of Fallot (TOF), the most common cyanotic congenital heart disease. Our objective is to study the impact of preoperative NLR on outcomes of TOF patients undergoing total repair.Entities:
Keywords: Biomarkers; Congenital Heart Disease; Inflammation; Intensive Care Units; Lymphocytes; Neutrophils; Tetralogy of Fallot
Mesh:
Year: 2021 PMID: 34236799 PMCID: PMC8597611 DOI: 10.21470/1678-9741-2020-0408
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Baseline characteristics of 116 patients with tetralogy of Fallot who underwent surgical correction from January 2014 to December 2018.
| Variable | Group I (69 patients) | Group II (47 patients) | |
|---|---|---|---|
| Gender (male:female) | 39:30:00 | 29:18:00 | 0.57 |
| Age (months) | 9 (IQR: 6 - 13) | 10 (IQR: 7- 26) | 0.09 |
| Weight (kg) | 7.5 (IQR: 6.6 - 8.6) | 7.8 (IQR: 5.9 - 10.5) | 0.60 |
| O2 saturation (%) | 92 (IQR: 87 - 95) | 90 (IQR: 85 - 95) | 0.41 |
| MPA size (mm) | 8 (IQR: 6 - 11) | 9 (IQR: 6 - 13) | 0.19 |
| Z-score for MPA (mm) | -1 (IQR: -1 and -1) | -4 (IQR: -5 and 0) | 0.65 |
| Preoperative ventricular dysfunction | 1 (1.4%) | 0 | 0.40 |
| Associated diagnosis | 23 (33.3%) | 19 (40.4%) | 0.43 |
| Preoperative mechanic ventilation | 2 (2.9%) | 4 (8.5%) | 0.18 |
| Genetic syndrome | 3 (4.3%) | 11 (23.4%) | 0.002 |
| Down syndrome | 2 (2.9%) | 7 (14.9%) | |
| DiGeorge syndrome | 0 | 2 (4.3%) | |
| Other | 1 (1.4%) | 2 (4.3%) | |
| Total neutrophil | 2948/mm3 (IQR: 2036 - 3694) | 5060/mm3 (IQR: 3713 - 6745) | < 0.001 |
| Total lymphocytes | 6811/mm3 (IQR: 5488 - 9067) | 3743/mm3 (IQR: 2684 - 4435) | < 0.001 |
| NLR | 0.44 (IQR: 0.33 - 0.60) | 1.37 (IQR: 1.03 - 1.97) | < 0.001 |
Statistically significant values are in bold (P<0.05)
IQR=interquartile range; MPA=main pulmonary artery; NLR=neutrophil-lymphocyte ratio
Intraoperative data complications and mortality of surgical correction of 116 patients with tetralogy of Fallot from January 2014 to December 2018.
| Variables | Group I (69 patients) | Group II (47 patients) | |
|---|---|---|---|
| CPB | 130 (IQR: 112 - 146) | 125 (IQR: 110 - 152) | 0.91 |
| Cross-clamping time | 103 (IQR: 88 - 116) | 97 (IQR: 82 - 117) | 0.46 |
| Transannular patch | 39 (56.5%) | 25 (53.2%) | 0.65 |
| Ventricular dysfunction | 6 (8.7%) | 2 (4.3%) | 0.35 |
| Associated procedures | 23 (33.3%) | 19 (40.4%) | 0.43 |
| ASD closure | 9 (13%) | 11 (23.4%) | |
| PDA occlusion | 4 (5.8%) | 2 (4.3%) | |
| PFO occlusion | 7 (10.1%) | 2 (4.3%) | |
| Pulmonary artery enlargement with patch | 1 (1.4%) | 4 (8.5%) | |
| ASD and pulmonary repair | 2 (2.9%) | 0 | |
| Complications | 10 (14.5%) | 8 (17%) | 0.71 |
| Neurologic | 3 (4.3%) | 2 (4.2%) | |
| Respiratory | 1 (1.4%) | 1 (2.1%) | |
| Infection | 1 (1.4%) | 3 (6.4%) | |
| Cardiogenic shock | 1 (1.4%) | 2 (4.2%) | |
| Others | 4 (5.8%) | 0 | |
| Arrhythmia | 6 (8.7%) | 5 (10.6%) | 0.72 |
| Readmission | 4 (5.8%) | 3 (6.4%) | 0.89 |
| In-hospital mortality | 1 (1.4%) | 4 (8.5%) | 0.13 |
ASD=atrial septal defect; CPB=cardiopulmonary bypass; IQR=interquartile range; PDA=patent ductus arteriosus; PFO=patent foramen ovale
Group I neutrophil-lymphocyte ratio (NLR) < 0.80 and Group II NLR ≥ 0.80
Fig. 1Demonstration of the association of a neutrophil-lymphocyte ratio > 0.80 with prolonged intensive care unit (ICU) length of stay (LOS) (A) and hospital LOS (B).
Fig. 2The receiver-operating characteristic analysis of preoperative neutrophil-lymphocyte ratio for postoperative hospital length of stay. The cutoff value was 0.80. The area under the curve was 0.801± 0.040 (95% confidence interval 0.722 - 0.879; P<0.001).
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| ASD | = Atrial septal defect | MPA | = Main pulmonary artery | |
| CHD | = Congenital heart disease | MV | = Mechanical ventilation | |
| CPB | = Cardiopulmonary bypass | NLR | = Neutrophil-lymphocyte ratio | |
| DS | = Down syndrome | PDA | = Patent ductus arteriosus | |
| ECMO | = Extracorporeal membrane oxygenation | PFO | = Patent foramen ovale | |
| HLOS | = Hospital length of stay | ROC | = Receiver-operating characteristic | |
| ICU | = Intensive care unit | SIRS | = Systemic inflammatory response syndrome | |
| IL | = Interleukins | TNF-α | = Tumor necrosis factor-alpha | |
| IQR | = Interquartile range | TOF | = Tetralogy of Fallot | |
| LOS | = Length of stay | X-clamp | = Cross-clamping | |
| miR | = Micro ribonucleic acid | |||
| Authors' roles & responsibilities | |
|---|---|
| VM | Substantial contributions to the conception and design of the work; and the acquisition and analysis of the data for the work; drafting the work; final approval of the version to be published |
| LAM | Substantial contributions to the conception and design of the work; drafting the work; final approval of the version to be published |
| GPG | Substantial contributions to the acquisition of data for the work; final approval of the version to be published |
| AT | Substantial contributions to the analysis of data for the work; final approval of the version to be published |
| RMS | Substantial contributions to the acquisition of data for the work; final approval of the version to be published |
| NF | Substantial contributions to the acquisition of data for the work; final approval of the version to be published |
| DFT | Substantial contributions to the acquisition of data for the work; final approval of the version to be published |
| LFC | Revising the work; final approval of the version to be published |
| FBJ | Revising the work; final approval of the version to be published |
| MBJ | Revising the work; final approval of the version to be published |